stockrow
Monday 9 November 2026
Export APMD’s income statement to Excel — free account
Apnimed, Inc.
APMDApnimed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, up 380.1% from fiscal 2024.
15.10
0.94
+6.64%
Follow APMD
Alert me
Apnimed, Inc. (APMD) P/E ratio
As of 6 November 2026, Apnimed, Inc. (APMD) trades at a P/E ratio of 0.8×. Over the past ten years it has ranged from 0.7× (November 2026) to 1.6× (August 2026); the current reading is higher than 4% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 1.3× | 0.00% |
| FY2024 | 1.3× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 1.3× | 0.00% |
| Mar 2026 | 1.3× | 0.00% |
| Jun 2025 | 1.3× | 0.00% |
| Mar 2025 | 1.3× | — |
Against its own ten years
Low 0.7×
High 1.6×
Ten-year median
1.3×
Current reading's percentile
4
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GERN Geron Corporation compare | n/m |
| OLMA Olema Pharmaceuticals, Inc. compare | n/m |
| DSGN Design Therapeutics, Inc. compare | n/m |
| AVBP ArriVent BioPharma, Inc. compare | n/m |
| KURA Kura Oncology, Inc. compare | n/m |
| IMMX Immix Biopharma, Inc. compare | n/m |
| NVCT Nuvectis Pharma, Inc. compare | n/m |
| APMD Apnimed, Inc. | 0.8× |
| OBX Obsidian Therapeutics, Inc compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)